Denali Therapeutics (DNLI) Invested Capital (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Invested Capital data on file, last reported at $926.1 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $926.1 million, down 18.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $926.1 million (down 18.13% YoY), and the FY2025 annual result was $1.0 billion, down 17.73% from the prior year.
• Invested Capital eased to $926.1 million in Q1 2026 per DNLI's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Invested Capital peaked at $1.5 billion in Q1 2024 and troughed at $812.7 million in Q3 2022.
• A 5-year average of $1.1 billion and a median of $1.0 billion in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital surged 50.56% in 2024, then declined 29.63% in 2025.
• A 5-year view of Invested Capital shows it stood at $1.0 billion in 2022, then decreased by 1.52% to $1.0 billion in 2023, then climbed by 20.18% to $1.2 billion in 2024, then declined by 17.73% to $1.0 billion in 2025, then dropped by 9.15% to $926.1 million in 2026.
• Business Quant data shows DNLI's Invested Capital at $926.1 million in Q1 2026, $1.0 billion in Q4 2025, and $931.8 million in Q3 2025.